Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease

European Journal of Endocrinology

Volumn 146, Issue 2, 2002, Pages 173-177

  Zimmermann Belsing, T ^a   Nygaard, B ^a   Rasmussen, A K ^a   Feldt Rasmussen, U ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; RECOMBINANT RECEPTOR; RECOMBINANT THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DEVICE; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RADIORECEPTOR ASSAY; RECURRENCE RISK; RELAPSE; SENSITIVITY AND SPECIFICITY; THYROTOXICOSIS;

EID: 0036174730     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1460173     Document Type: Article

References (34)

1. Autoantibodies to the thyrotropin receptor
2. Autoimmune thyroid disease: Further developments in our understanding
3. The thyrotropin (TSH) receptor: Interaction with TSH and autoantibodies
4. New assay systems for thyrotropin receptor antibodies
5. Thyrotropin-receptor antibodies in thyroid diseases: Advances in detection techniques and clinical applications
6. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease
7. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease
8. Detecting TSH-receptor antibodies with the recombinant TBII assay: Technical and clinical evaluation
9. Clinical applications of the 2nd generation assay for anti-TSH receptor antibodies in Graves' disease. Evaluation in patients with negative 1st generation test
10. Clinical validity of a new commercial method for detection of TSH- receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs
11. Clinical value of a new TSH binding inhibitory activity assay using human TSH receptors in the follow-up of antithyroid drug-treated Graves' disease. Comparison with thyroid stimulating antibody bioassay
12. Thyroid controversy-stimulating antibodies
13. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease
14. The prognostic value of thyrotropin receptor antibody (TRAb) levels in Graves' disease
15. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States
16. Do thyrotropin receptor antibodies (TRAb) predict relapse after antithyroid drug treatment of Graves' disease
17. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs
18. Antithyroid drugs and Graves' disease - Prospective randomized assessment of long-term treatment
19. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs
20. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment
21. Immunological aspects of Graves' disease and importance of thyroid stimulating immunoglobulins
22. A luminescent bioassay for thyroid blocking antibodies
23. Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor
24. The management of hyperthyroidism due to Graves' disease in Japan in 1988
25. Reassessment of antithyroid drug therapy of Graves' disease
26. Goitre size and outcome of medical treatment of Graves' disease
27. Prediction of relapse in drug-treated Graves' disease using thyroid stimulation indices
28. Prediction of outcome in Graves' disease after carbimazole treatment
29. Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy
30. Serum thyroglobulin and thyroglobulin auto-antibodies in thyroid disease
31. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease
32. Prediction of the long-term results of antithyroid drug therapy for thyrotoxicosis
33. Pituitary-thyroid feedback regulation in patients with Graves' disease during antithyroid drug therapy
34. Guidelines for TSH-receptor antibody measurements in pregnancy: Results of an evidence-based symposium organized by the European Thyroid Association